Listar DG - Artículos por financiación

Mostrando ítems 1-6 de 6

      Financiación
      We acknowledge the Spanish Government (Grant No. BIO2008-01353) and the Spanish Junta de Andalucía (Grant Nos. P06-FQM1858 and P07-FQM3163) financial support. MH acknowledges financial support from the 'Juan de la Cierva' grant from the Spanish Government. GB acknowledges financial support from the 'Programa de formación de investigadores del Departamento de Educación, Universidades e Investigación' grant from the Basque Country Government. [1]
      We thank Banco Nacional de ADN (University of Salamanca, Spain) and the Norwegian Bone Marrow Donor Registry, who supplied part of the control DNA samples. We are also thankful to EUSTAR (the EULAR Scleroderma Trials and Research group) and the German Network of Systemic Sclerosis for the facilitation of this project. This work was supported by the following grants: JM was funded by GEN- FER from the Spanish Society of Rheumatology, SAF2009-11110 from the Spanish Ministry of Science, CTS-4977 from Junta de Andalucía, Spain, in part by Redes Temáticas de Investigación Cooperativa Sanitaria Program, RD08/ 0075 (RIER) from Instituto de Salud Carlos III (ISCIII), Spain and by Fondo Europeo de Desarrollo Regional (FEDER). TRDJR was funded by the VIDI laureate from the Dutch Association of Research (NWO) and Dutch Arthritis Foundation (National Reumafonds). JM and TRDJR were sponsored by the Orphan Disease Program grant from the European League Against Rheumatism (EULAR). BPCK is supported by the Dutch Diabetes Research Foundation (grant 2008.40.001) and the Dutch Arthritis Foundation (Reumafonds, grant NR 09-1-408). TW was granted by DFG WI 1031/6.1. This study was also funded by PI-0590-2010, Consejería de Salud, Junta de Andalucía, Spain. [1]
      We thank the National DNA Bank Carlos III (University of Salamanca, Spain) for supplying part of the control DNA samples from Spain, as well as all patients and controls for kindly agreeing to their essential collaboration. This work was supported by the Spanish Ministry of Economy and Competitiveness through the Spanish National Plan for Scientific and Technical Research and Innovation (ref. SAF2016- 78722-R) the “Ramón y Cajal” program (ref. RYC-2014- 16458) and the “Juan de la Cierva Incorporación” program (ref. IJC2018- 038026-I), which include FEDER funds. AG-J was recipient of a grant from the "Plan Propio" program of the University of Granada ("Becas de Iniciación a la Investigación para estudiantes de Grado,” conv. 2019). SL received support from the Spanish Ministry of Science and Innovation (grants FIS-ISCIII DTS18/00101, co-funded by FEDER funds/European Regional Development Fund (ERDF)—a way to build Europe) and from Generalitat de Catalunya (grant 2017SGR191). SL is sponsored by the “Researchers Consolidation Program” from the SNS-Dpt. Salut Generalitat de Catalunya (Exp. CES09/020). JG was partially funded by FCT/MCTES, through national funds attrib-uted to Center for Toxicogenomics and Human Health—ToxOmics (UIDB/00009/2020). PIM is supported by the FCT post-doctoral fel-lowship (SFRH/BPD/120777/2016), financed from the Portuguese State Budget of the Ministry for Science, Technology and High Education and from the European Social Fund, available through the Programa Operacional do Capital Humano. [1]
      Western Norway Regional Health Authority (Helse Vest) 911807 912043 [1]
      Worldwide Cancer Research 15-1005 [1]
      Worldwide Cancer Research (AICR) 15-1005 [1]